These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35402282)

  • 1. Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives.
    Abdel-Razeq H; Tamimi F; Abujamous L; Abdel-Razeq R; Abunasser M; Edaily S; Abdulelah H; Khashabeh RA; Bater R
    Front Oncol; 2022; 12():673094. PubMed ID: 35402282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
    Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns and Prevalence of
    Abdel-Razeq H; Tamimi F; Abujamous L; Edaily S; Abunasser M; Bater R; Salama O
    Cancer Manag Res; 2021; 13():4597-4604. PubMed ID: 34135636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer.
    Abdel-Razeq H; Abujamous L; Al-Azzam K; Abu-Fares H; Bani Hani H; Alkyam M; Sharaf B; Elemian S; Tamimi F; Abuhijla F; Edaily S; Salama O; Abdulelah H; Daoud R; Abubaker M; Al-Atary A
    Breast Cancer (Dove Med Press); 2023; 15():1-10. PubMed ID: 36660366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
    J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 9. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
    Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
    Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants.
    Park KS; Cho EY; Nam SJ; Ki CS; Kim JW
    Genet Med; 2016 Dec; 18(12):1250-1257. PubMed ID: 27124784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?
    Kwong A; Ho CYS; Shin VY; Au CH; Chan TL; Ma ESK
    BMC Med Genomics; 2022 May; 15(1):122. PubMed ID: 35641994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
    Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic, Surgical and Oncological Approach to Breast Cancer, with
    Subaşıoğlu A; Güç ZG; Gür EÖ; Tekindal MA; Atahan MK
    Eur J Breast Health; 2023 Jan; 19(1):55-69. PubMed ID: 36605468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    Chang J; Seng S; Yoo J; Equivel P; Lum SS
    Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.
    Lindor NM; Goldgar DE; Tavtigian SV; Plon SE; Couch FJ
    Oncologist; 2013; 18(5):518-24. PubMed ID: 23615697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
    van Marcke C; Collard A; Vikkula M; Duhoux FP
    Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk management decisions in women with BRCA1 and BRCA2 mutations.
    Morgan R; Brown A; Hamman KJ; Sampson J; Naik A; Massimino K
    Am J Surg; 2018 May; 215(5):899-903. PubMed ID: 29499861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic germline variants in patients with breast cancer: conversations across generations, practices and patients' attitude.
    Abdel-Razeq H; Mustafa R; Abdel-Razeq S; Abu-Fares H; Al Masri S; Damsees R; El-Atrash M; Elemian S; Alkyam M; Ammar K; Bater R; Kderat M; Alhajahjeh A
    Front Genet; 2023; 14():1194075. PubMed ID: 37920853
    [No Abstract]   [Full Text] [Related]  

  • 20. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling.
    Richter S; Haroun I; Graham TC; Eisen A; Kiss A; Warner E
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii69-viii74. PubMed ID: 24131974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.